Epigenetic alterations, including DNA methylation, histone modifi cation, loss of genome imprinting, chromatin remodeling and non-coding RNAs, are associated with human carcinogenesis. Among them, DNA methylation is a fundamental epigenetic process to modulate gene expression. In cancer cells, altered DNA methylation includes hypermethylation of site-specifi c CpG island promoter and global DNA hypo-methylation. Detection of aberrant gene promoter methylation has been applied to the clinic to stratify risk in cancer development, detect early cancer and predict clinical outcomes. Environmental factors associated with carcinogenesis are also signifi cantly related to aberrant DNA methylation. Importantly, epigenetic changes, including altered DNA methylation, are reversible and thus, used as targets for cancer therapy or chemoprevention. An increasing number of recent studies reported DNA methylation level to be a useful biomarker for diagnosis, risk assessment and prognosis prediction for gastrointestinal (GI) cancers. This review summarized the accumulated evidence for clinical application to use aberrant DNA methylation levels in GI cancers, including colorectal, gastric and esophageal cancer.
Introduction
Epigenetics refers to heritable changes in gene expression that, unlike mutations, are not attributable to alterations in genomic DNA sequences. Epigenetic changes, such as DNA methylation, histone modifi cations, and altered expression of microRNAs, can regulate gene expression through mechanisms other than changes in genomic DNA sequence. Among them, genomic DNA methylation is a major epigenetic mechanism to mediate the X-chromosome inactivation, imprinting and repression of endogenous retroviruses. [1] [2] [3] [4] DNA methylation is the covalent post-replicative addition of a methyl group (-CH 3 ) to the 5-carbon of the cytosine ring in CpG dinucleotides. CpG dinucleotides are non-uniformly distributed throughout the human genome. [2] [3] [4] Regions of the genome that are rich in sequences of a cytosine preceding a guanine (CpG dinucleotide) are known as CpG islands, which in particular, exist in the promoter regions of approximately half of all coding genes.
Altered DNA methylation in human cancers includes hypermethylation of site-specifi c CpG island promoter and global DNA hypo-methylation. [1] [2] [3] [4] DNA methylation in gene promoter CpG islands results in its transcriptional inactivity and silence of protein expression. Thus, hypermethylation of a gene promoter is now recognized as a means of silencing tumor suppressor genes with effects similar to those of mutation or allelic loss in the development of cancer or other diseases. [3] Another DNA methylation alteration in human cancer is genome-wide DNA hypo-methylation. [5] Genome-wide DNA hypo-methylation appears to play an important role in genomic instability, leading to cancer development. [6] [7] [8] Previous experimental studies demonstrated that DNA hypo-methylation of repetitive sequences, that is, short interspersed transposable elements (SINE or Alu elements) or long interspersed transposable elements (LINEs) may predispose cells to chromosomal defects and rearrangements, resulting in genetic instability. [6] As LINE-1 constitutes a substantial portion (approximately 17%) in the human genome, levels of LINE-1 methylation are regarded to be surrogate markers for global DNA methylation. [9] Thus, epigenetic regulation of gene expression has emerged as a fundamental way in pathogenesis of numerous malignancies, including cancers of the digestive system. In fact, many exciting discoveries in epigenetics have emerged from the study of gastrointestinal (GI) cancers. In this review, we summarized the accumulated evidence supporting the clinical application of DNA methylation level in diagnosis of esophageal, gastric and colorectal cancers.
Altered DNA Methylation in Esophageal Cancer
Esophageal cancer can be classifi ed into two histological types, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma ( EAC). Their incidences vary notably by geographic distribution. ESCC accounts for approximately 90% of the esophageal cancers in East Asian countries, [10, 11] whereas the highest number of EAC is found in Northern and Western Europe, North America and Oceania. [12] These two subtypes also have different epigenetic alterations. Growing evidence suggests that there is a fi eld of epigenetic changes in esophageal cancer [13] [14] [15] by particularly emphasized signifi cance of promoter hypermethylation of 14 specifi c genes (SFRP1, SFRP2, DCC, APC, p16, p14, APBA1, APBA2, APBA3, CACNA1G, PTGS2, DAPK1, MLH1 and MGMT) in non-cancerous mucosae from ESCC patients vs. mucosae from healthy volunteers, [13] indicating that aberrant methylation or these 14 gene promoters in esophageal mucosae is associated with ESCC development. An overview of different previous studies of clinical implications of DNA methylation in esophageal cancer is provided in Table 1 . Aberrant promoter methylation of tumor suppressor genes has also been used to predict clinical outcomes following curative ESCC resections. For example, promoter methylation of APC has been associated with reduced survival of ESCC patients after esophagectomy. [16] Ling et al. [17] showed that MSH2 promoter hypermethylation in circulating tumor DNA was a valuable predictor of disease-free survival of ESCC patients after esophagectomy. Aberrant methylation of FHIT was also reported to be associated with exposure to tobacco smoking and individuals with early-stage ESCC whose tumors exhibited FHIT hypermethylation had poor prognoses. [18] CDH1 hypermethylation was detected in 14-61% of ESCC, which was associated with recurrence of early-stage ESCC. [19] Moreover, aberrantly methylated gene promoters were also detected in plasma or sera of ESCC patients. Hibi et al. [20] showed that p16 promoter methylation in ESCC specimens had this same methylation change in their serum DNA in 23% the of patients, which implied that detection of serum DNA p16 promoter methylation could serve as a tumor marker. However, few studies have addressed or detected DNA hypo-methylation in ESCC. LINE-1 methylation is regarded as a surrogate marker for global DNA methylation. To better understand DNA methylation in ESCC tissues, our group measured their LINE-1 methylation using the pyrosequencing technology. Chronic tobacco smoking and heavy alcohol drinking are established as risk factors for ESCC development. [21] [22] [23] [24] [25] LINE-1 hypo-methylation is signifi cantly associated with tobacco smoking, which supports its plausibility as a surrogate marker for an epigenetic fi eld defect. [26] LINE-1 methylation is highly variable among ESCC specimens (25-92%) and its hypo-methylation is strongly associated with poor ESCC prognosis. [27] Moreover, loss of insulin-like growth factor 2 (IGF2) imprinting has been found in ESCC and loss of IGF2 methylation is associated with shorter survival of patients. [28] [29] In Barrett's esophagus, a pre-malignant condition that can lead to EAC development, aberrant DNA methylation has also been shown to occur in promoters of tumor suppressor genes, adhesion molecules and DNA repair genes (AKAP12, APC, CDH13, DAPK1, GPX, GST, MGMT, NELL1, REPRIMO/RPRM, p16, SFRP, SOCS, SST, TAC1, TIMP3 and WIF1). [30] Jin et al. reported that promoter hypermethylation of eight genes (p16, RUNX3, HPP1, NELL1, TAC1, SST, AKAP12 and CDH13) could predict neoplastic progression risk in Barrett's esophagus. [31] However, in the study of DNA hypo-methylation in Barrett's EAC (BAC), Alvarez et al. reported a predominance of DNA hypo-methylation rather than DNA hyper-methylation in early-stage of BAC carcinogenesis. They also detected DNA hypo-methylation in a series of genes associated with the immune system such as chemokines (CXCL1 and CXCL3). [32] 
Altered DNA Methylation in Gastric Cancer
Gastric cancer is the fourth most frequently diagnosed cancer and the second leading cause of cancer-related deaths in the world. [33] Gastric adenocarcinoma accounts for 90-95% of gastric cancer and has two histological subtypes (intestinal and diffuse) based on microscopic observation and tumor growth patterns, which differ widely in molecular pathogeneses. [34] Nonetheless, epigenetic alterations play important roles in the development of both gastric carcinoma types. Gene promoter methylation has been reported to associate with gastric cancer development, such as CDKN2A, CDK2AP2,  CDH1, MGMT, RASSF1, RUNX3, DLC1, ITGA4, ZIC1,  PRDM5, PCDH10, TFPI2, RUNX3, SPINT2, BTG4,  SFRP2, hMLH1, DKK-3, TCF4, GRIK2, RAR, CHFR,  BNIP3 , RASSF1A, LRP1B and SFRP5, promoter of which was more frequently methylated in gastric cancer tissues than those of the corresponding normal gastric tissue. [35, 36] Furthermore, promoter methylation of many genes with different biological functions has been associated with the clinicopathological characteristics and prognosis of gastric cancer [ Table 2 ]. [37] Of these genes, promoter hypermethylation of CDH1 [38] and MGMT [39, 40] was associated with worse outcomes of gastric cancer patients after surgery. However, patients with hypermethylated IGF2 in blood leukocyte DNA reportedly had a signifi cantly better survival rate than those with hypo-methylated IGF2. [41] Additionally, DNA methylation of detected in body fl uids that can be obtained non-invasively, such as serum and gastric washes, may have a clinical application for gastric cancer; for example, detection of aberrant DNA methylation of CDH1, DAPK, GSTP1, p15, p16, RARβ, RASSF1A, RUNX3 and TFPI2 in serum may be a useful biomarker for gastric cancer. [42] Environmental factors also signifi cantly affect DNA methylation. Etiological studies have closely associated two distinct infectious agents, Helicobacter [43, 44] Previous prospective studies showed that H. pylori infection had an essential role in gastric carcinogenesis [43] and the mechanisms, underlying gastric carcinogenesis due to H. pylori-induced DNA methylation, had been indicated. H. pylori infection induced aberrant promoter methylation in tumor-suppressor genes, such as RUNX3, p16, LOX and CDH1. [45, 46] Furthermore, IL-1β is thought to be especially signifi cant as a specifi c single-nucleotide polymorphism of IL-1β in association with increases in both gastric cancer risk and incidence. [47, 48] EBV infection occurs at a very early-stage in cancer development and plays an important role in gastric carcinogenesis. Aberrant methylation of tumor suppressor genes, such as CDH1, p15, p16 and p73, is frequently observed in EBV-associated gastric cancer but is less frequently detected in adjacent non-neoplastic mucosa, [49] [50] [51] [52] which suggests that aberrant methylation is a critical mechanism of EBV-related gastric tumorigenesis. Regarding the molecular mechanisms underlying host DNA methylation during early-stage EBV infection in gastric epithelium, LMP2A expression was upregulated through STAT3 phosphorylation, which further induced DNA methyltransferases during EBV infection. [53] However, few studies addressed or detected DNA hypo-methylation in gastric cancer. In gastric cancer, global genomic hypo-methylation has been found in premalignant stages of the disease. [54] In our previous study that assessed 203 resected gastric cancer specimens, we found gastric cancer tissues had signifi cantly lower LINE-1 methylation levels than that of their matched normal gastric mucosa. LINE-1 hypo-methylation in gastric cancer was also associated with shorter survival of patients. [55] Moreover, LINE-1 hypo-methylation of non-cancerous gastric mucosae in gastric cancer patients signifi cantly correlated with H. pylori infection. [56] Hur et al. reported that gastric cancer tissues had conspicuously higher expression of SULF1 regulated by promoter hypo-methylation than that of the normal mucosa. SULF1 is also an independent prognostic factor, and LN is a metastasis predictive factor in gastric cancer patients. [57] 
Altered DNA Methylation in Colorectal Cancer
Aberrant DNA methylation was reported as an important hallmark of colorectal cancer. Colorectal cancer is a heterogeneous disease and molecularly, it can be classifi ed into three major molecular subtypes, that is, microsatellite instability (MSI), chromosomal instability and CpG island methylator phenotype (CIMP). [58] In 1999, Baylin and Issa et al. coined the term "CpG island methylator phenotype" or CIMP, in which promoter of tumor suppressor genes was methylated to contribute to tumorigenesis at least in theory through progressive genetic silence, possibly even in the absence of any genetic mutations. [59] According to epigenetic and clinical profi les, primary colorectal cancer is divided into three distinct subclasses, that is, CIMP1, CIMP2 and CIMP-negative. CIMP1 tumor often shows mutations of MSI (80%) and BRAF (53%) while CIMP2 tumor often shows K-RAS mutation (92%) but rarely shows MSI or BRAF or TP53 mutations. Non-CIMP tumor has a high frequency of TP53 mutations (71%). [60] CIMP1 has a favorable prognosis, whereas CIMP2 is associated with poor prognosis. [60] Cancer CIMP status has been assessed as a predictive marker for 5-FU responsiveness. [61] Colorectal cancer with CIMP is distinct from those with chromosomal instability, and there are two forms of nuclear derangement represented alternative pathways for colorectal cancer development, [62, 63] which overlap somewhat as hypermethylation can occur in APC and is part of the chromosomal instability pathway, [64] or in the MLH1 gene, triggering MSI. [65] MLH1 accounts for approximately 40% of the cases of the hereditary colorectal cancer and Lynch syndrome. [66] Detection of MLH1 methylation is currently used to discriminate between sporadic colorectal cancer with MSI and familial forms (Lynch syndrome). [67] Methylation of MGMT promoter also occurs during colorectal cancer progression in either pathway and may facilitate the accumulation of point mutations as tumors evolve. [65] The CpG island methylation affects a number of genes in colon cancer, and signifi cance of these epigenetic alterations in colon cancer pathogenesis has been widely reported. [68, 69] Hundreds of gene promoters have been found to be aberrantly methylated in the average colorectal cancer genome and their number is ever-growing, including genes of the Wnt signaling pathway such as APC, AXIN2, DKK1, SFRP1, SFRP2 and WNT5A, the DNA repair genes MGMT, hMLH1 and hMLH2, cell cycle-related genes such as p14, p15 and p16, RAS signaling genes RASSF1A and RASSF1B and many more. [70, 71] Several DNA methylation markers have been proposed as useful early biomarkers for colorectal cancer early detection and prediction of prognosis. For instance, methylation of MLH1 can be detected in colorectal cancer tissue samples [72] or blood [73] to help interpret MSI because its presence helps to exclude diagnosis of Lynch syndrome. The presence of aberrantly methylated SEPT9 (which encodes a GTPase that is involved in dysfunctional cytoskeletal organization) in plasma is a valuable and minimally invasive blood-based polymerase chain reaction test with a sensitivity of almost 70% and a specifi city of 90% in colorectal cancer detection. [74] [75] [76] [77] [78] In fact, an assay that detects hypermethylated SEPT9 is now being commercialized and offered in some parts of Europe to screen colorectal cancer. Moreover, detection of aberrant methylation of vimentin in fecal DNA was reported in colorectal cancer when compared with normal control; [79] the sensitivity and specifi city of methylated vimentin for colorectal cancer were 88% and 87%, respectively. [80] Kamimae et al. have recently shown that detection of DNA methylation in mucosal wash fl uid from patients undergoing colonoscopy may be a good molecular marker for predicting invasiveness of colorectal tumors. [81] Promoter hypermethylation of MLH1, MGMT and HIC1 can be detrimental and lead to cancer progression. [82] [83] [84] [85] Seven additional genes (TIMP3, CXCL12, ID4, IRF8, CHFR, IGFBP3 and CD109) were frequently methylated in late-stage colorectal cancer and could have a role in colorectal cancer progression and metastasis. [71, 86, 87] Yi et al. observed that colorectal cancers that have silenced (methylated) genes in the extracellular matrix-remodeling pathway, such as IGFBP3, EVL, CD109 and FLNC, showed worse survival, suggesting that methylation of this pathway-related genes might represent a prognostic signature for colorectal cancer patients. [87] Moreover, hypo-methylation of the IGF2 differentially methylated region in colorectal tumors was associated with poor prognosis. [88] However, all of these possible markers need to be further validated before they are used clinically.
Global hypo-methylation may infl uence tumor progression by making chromosomes more susceptible to breakage and causing disruption of normal gene structure and function, leading to reactivating previously silenced retrotransposons. [89] [90] [91] Most recent research on LINE-1 methylation levels in GI cancers has focused on colorectal cancer; Ogino et al. reported LINE-1 methylation levels widely occurred and approximately normally distributed (range: 23.1-90.3%) in a cohort of 869 colorectal cancer patients. [92] LINE-1 hypo-methylation was inversely associated to the MSI and CIMP; [92, 93] these fi ndings suggest that CIMP/MSI and genomic hypo-methylation represent different pathways in colorectal cancer development. A summary of reported gene methylation in stool, blood and tissue samples of patients with colorectal cancer is shown in Tables 3 and 4 . 
Conclusion
In this review, we have summarized the main epigenetic alterations in GI cancer-global DNA hypo-methylation and site-specifi c CpG island promoter hypermethylation with clinical characteristics in patients with GI cancers. Epigenetic signatures have a potential usefulness in early diagnosis, screening, monitoring and prediction of prognoses or therapy responses for GI cancer patients. Further investigation in this fi eld would increase our knowledge of epigenetic alterations of GI cancer and help to develop novel therapeutic strategies for GI cancers.
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